Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Brixner

Showing results (21-30 of 102) with videos related to

Pageof 11
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 30, 2024
An evaluation of vilobelimab (anti-C5a) as a cost-effective option to treat severely ill mechanically ventilated patients with COVID-19Daniel C Malone, Joseph Biskupiak, Diana Brixner, et al.
Journal of Managed Care Pharmacy : JMCP|February 5, 2008
The challenge of compliance and persistence: focus on ulcerative colitisSunanda V Kane, Diana Brixner, David T Rubin, et al.
Disease Management : DM|January 27, 2005
Impact of a seizure disorder disease management program on patient-reported quality of lifeMargaret J Gunter, Diana Brixner, Ann von Worley, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 3, 2009
Toward a consensus on the QALYMichael Drummond, Diana Brixner, Marthe Gold, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 24, 2020
Barriers and facilitators of exploiting the potential of value-added medicinesZsuzsanna Ida Petykó, András Inotai, Anke-Peggy Holtorf, et al.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
Payer perceptions on the use of economic models in oncology decision makingJoseph Biskupiak, Gary Oderda, Diana Brixner, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 20, 2013
Outcomes associated with nonconcordance to National Kidney Foundation guideline recommendations for oral antidiabetic drug treatments in patients with concomitant type 2 diabetes and chronic kidney diseaseShih-Yin Chen, Yuan-Chi Lee, Veronica Alas, et al.
Multiple Sclerosis and Related Disorders|July 20, 2019
Patients' preferences and willingness-to-pay for disease-modifying therapiesNatasha Frost, Jerome Freeman, Diana Brixner, et al.
Value in Health Regional Issues|October 28, 2017
Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging MarketsDiana Brixner, Nikos Maniadakis, Zoltán Kaló, et al.
Journal of Managed Care & Specialty Pharmacy|September 18, 2025
AMCP real-world evidence standards: Overcoming barriers to using real-world evidence in US payer decision-makingCatherine M Lockhart, Elizabeth Powers, Brian Sweet, et al.
Pageof 11

Showing results (21-30 of 102) with videos related to

Sort By:
Pageof 11
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 30, 2024
An evaluation of vilobelimab (anti-C5a) as a cost-effective option to treat severely ill mechanically ventilated patients with COVID-19Daniel C Malone, Joseph Biskupiak, Diana Brixner, et al.
Journal of Managed Care Pharmacy : JMCP|February 5, 2008
The challenge of compliance and persistence: focus on ulcerative colitisSunanda V Kane, Diana Brixner, David T Rubin, et al.
Disease Management : DM|January 27, 2005
Impact of a seizure disorder disease management program on patient-reported quality of lifeMargaret J Gunter, Diana Brixner, Ann von Worley, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 3, 2009
Toward a consensus on the QALYMichael Drummond, Diana Brixner, Marthe Gold, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 24, 2020
Barriers and facilitators of exploiting the potential of value-added medicinesZsuzsanna Ida Petykó, András Inotai, Anke-Peggy Holtorf, et al.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
Payer perceptions on the use of economic models in oncology decision makingJoseph Biskupiak, Gary Oderda, Diana Brixner, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 20, 2013
Outcomes associated with nonconcordance to National Kidney Foundation guideline recommendations for oral antidiabetic drug treatments in patients with concomitant type 2 diabetes and chronic kidney diseaseShih-Yin Chen, Yuan-Chi Lee, Veronica Alas, et al.
Multiple Sclerosis and Related Disorders|July 20, 2019
Patients' preferences and willingness-to-pay for disease-modifying therapiesNatasha Frost, Jerome Freeman, Diana Brixner, et al.
Value in Health Regional Issues|October 28, 2017
Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging MarketsDiana Brixner, Nikos Maniadakis, Zoltán Kaló, et al.
Journal of Managed Care & Specialty Pharmacy|September 18, 2025
AMCP real-world evidence standards: Overcoming barriers to using real-world evidence in US payer decision-makingCatherine M Lockhart, Elizabeth Powers, Brian Sweet, et al.
Pageof 11